AP
$0.68
-0.02
(-3.51%)
As of Oct 5, 2026, 5:11 PM EDT
Price history
Aprea Therapeutics (APRE) is trading down at $0.68 (-3.51%), as of the latest quote. It operates in the Health Care sector.
IPO: October 3, 2019 · $15.00 offering · NASDAQ · View IPO details →
Aprea Therapeutics net income history (FY2017–FY2025)
Net income
| FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Operating income | — | — | — | — | −$37.4M | −$113.4M | −$15.5M | −$14.3M | −$13.2M |
| Net income | −$15.2M | −$15.5M | −$28.1M | −$53.5M | −$37.1M | −$112.7M | −$14.3M | −$13.0M | −$12.6M |
| EPS (diluted) | −$5268.00 | −$5380.00 | −$93.40 | −$50.61 | −$34.88 | −$67.99 | −$3.95 | −$2.35 | −$1.93 |
| Balance sheet | |||||||||
| Cash and equivalents | $24.4M | $65.7M | $130.1M | $89.0M | $53.1M | $28.8M | $21.6M | $22.8M | $14.6M |
| Total assets | — | $66.0M | $133.6M | $92.8M | $56.8M | $30.2M | $22.7M | $24.0M | $15.9M |
| Total liabilities | — | $4.87M | $9.36M | $15.4M | $7.32M | $3.20M | $5.70M | $4.67M | $3.49M |
| Shareholders' equity | −$35.8M | −$51.4M | $124.2M | $77.4M | $49.5M | $25.6M | $17.0M | $19.3M | $12.4M |
| Cash flow | |||||||||
| Operating cash flow | −$14.0M | −$15.3M | −$26.7M | −$41.8M | −$37.7M | −$25.0M | −$12.2M | −$13.6M | −$12.9M |
| Capital expenditure | — | $3.70K | $30.9K | $25.7K | — | — | $93.1K | $15.5K | — |
| Free cash flow | — | −$15.3M | −$26.7M | −$41.8M | — | — | −$12.3M | −$13.6M | — |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$4.10M | −$3.23M | −$4.09M | −$3.39M | −$3.12M | −$2.64M | −$3.43M | −$4.03M |
| Net income | −$3.78M | −$2.89M | −$3.93M | −$3.24M | −$2.97M | −$2.46M | −$3.29M | −$3.59M |
| EPS (diluted) | −$0.64 | −$0.46 | −$0.66 | −$0.53 | −$0.47 | −$0.27 | −$0.22 | −$0.07 |
| Balance sheet | ||||||||
| Cash and equivalents | $26.2M | $22.8M | $19.3M | $16.5M | $13.7M | $14.6M | $46.5M | $41.2M |
| Total assets | $26.9M | $24.0M | $20.2M | $17.3M | $14.3M | $15.9M | $47.6M | $42.3M |
| Total liabilities | $4.95M | $4.67M | $4.67M | $3.90M | $3.41M | $3.49M | $6.02M | $3.82M |
| Shareholders' equity | $21.9M | $19.3M | $15.5M | $13.4M | $10.9M | $12.4M | $41.6M | $38.5M |
| Cash flow | ||||||||
| Operating cash flow | −$2.47M | −$3.51M | −$3.63M | −$3.13M | −$3.17M | −$2.96M | −$2.76M | −$3.28M |
| Capital expenditure | $0 | $0 | — | — | — | — | — | — |
| Free cash flow | −$2.47M | −$3.51M | — | — | — | — | — | — |
From Aprea Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Aprea Therapeutics
- Headquarters
- Doylestown, Pennsylvania From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with APRE
- ANVS Annovis Bio
- AORT Artivion Inc
- APGE Apogee Therapeutics Inc
- APMD Apnimed
- APUS Apimeds Pharmaceuticals US
- AQST Aquestive Therapeutics Inc
- ARAY Accuray Inc
- ARCT Arcturus Therapeutics Holdings Inc